Examining connections between screening for breast, cervical and prostate cancer and colorectal cancer screening.

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2014-06-01 DOI:10.2217/crc.14.18

Michael D Wirth, Heather M Brandt, Heather Dolinger, James W Hardin, Patricia A Sharpe, Jan M Eberth

{"title":"Examining connections between screening for breast, cervical and prostate cancer and colorectal cancer screening.","authors":"Michael D Wirth, Heather M Brandt, Heather Dolinger, James W Hardin, Patricia A Sharpe, Jan M Eberth","doi":"10.2217/crc.14.18","DOIUrl":null,"url":null,"abstract":"Aim: To compare participation in breast, cervical and prostate cancer screening with colorectal cancer (CRC) screening.Materials & methods: This random digit-dialed survey includes participants (aged 50-75 years) from South Carolina (USA). Past participation information in fecal occult blood test, flexible sigmoidoscopy, colonoscopy, mammography, clinical breast examination, Pap test, prostate-specific antigen and digital rectal examination was obtained.Adjusted odds ratios are reported.Results: Among European-American women, any cervical or breast cancer screening was associated with adherence to any CRC screening. Among African-American women, mammography was associated with adherence to any CRC screening. Digital rectal examination and prostate-specific antigen tests were associated with adherence to any CRC screening test among all men.Conclusion: Future research should explore approaches inclusive of cancer screening recommendations for multiple cancer types for reduction of cancer screening disparities.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"3 3","pages":"253-263"},"PeriodicalIF":2.7000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/crc.14.18","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/crc.14.18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 16

Abstract

Aim: To compare participation in breast, cervical and prostate cancer screening with colorectal cancer (CRC) screening.

Materials & methods: This random digit-dialed survey includes participants (aged 50-75 years) from South Carolina (USA). Past participation information in fecal occult blood test, flexible sigmoidoscopy, colonoscopy, mammography, clinical breast examination, Pap test, prostate-specific antigen and digital rectal examination was obtained.Adjusted odds ratios are reported.

Results: Among European-American women, any cervical or breast cancer screening was associated with adherence to any CRC screening. Among African-American women, mammography was associated with adherence to any CRC screening. Digital rectal examination and prostate-specific antigen tests were associated with adherence to any CRC screening test among all men.

Conclusion: Future research should explore approaches inclusive of cancer screening recommendations for multiple cancer types for reduction of cancer screening disparities.

查看原文本刊更多论文

研究乳腺癌、子宫颈癌和前列腺癌筛查与结直肠癌筛查之间的联系。

目的:比较乳腺癌、宫颈癌和前列腺癌与结直肠癌(CRC)筛查的参与情况。材料与方法:这项随机数字拨号调查包括来自南卡罗来纳州(美国)的参与者(年龄50-75岁)。获得以往参与粪便隐血检查、乙状结肠镜检查、结肠镜检查、乳房x光检查、临床乳腺检查、巴氏涂片检查、前列腺特异性抗原和直肠指检的信息。报告了调整后的优势比。结果:在欧美女性中，任何宫颈癌或乳腺癌筛查与任何CRC筛查的依从性相关。在非裔美国女性中，乳房x光检查与CRC筛查的依从性相关。直肠指检和前列腺特异性抗原检测与所有男性CRC筛查试验的依从性相关。结论:未来的研究应探索包括多种癌症类型的癌症筛查建议在内的方法，以减少癌症筛查的差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.